TG Therapeutics (NASDAQ:TGTX) is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of hematologic malignancies and autoimmune diseases. Their pipeline consists of innovative, novel treatments aimed at improving the quality of life for patients with B-cell malignancies and autoimmune diseases. With a commitment to addressing unmet medical needs, TG Therapeutics is dedicated to advancing its research and development projects to bring next-generation therapies to the market. Targeting specific diseases with precision medicine, their objective is to provide more effective and less toxic treatment options, spearheading a new era in patient care.